A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the safety and tolerability of AZD7762 alone and in combination with Gemcitabine
Assessed after each course of treatment
No
Peter Langmuir, M.D.
Study Director
AstraZeneca
United States: Food and Drug Administration
D1040C00002
NCT00413686
December 2006
May 2010
Name | Location |
---|---|
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |